Evidence map›Paper›PMID 41608982›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

IGF-1 Deficiency Serves as an Integrated Biomarker Pathogenic Driver and Predictor in Poor Ovarian Response.

Zhu Hu, Yuanyuan Yu, Guanyou Huang, Jinnan Li, Chao Yang, Aizhuan Long, Jia Tang, Tengxiang Chen, Shuyun Zhao, Tuo Zhang

Abstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Zhu HuReproductive Medicine Center, the Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, China.
Yuanyuan YuTransformation Engineering Research Center of Chronic Disease Diagnosis and Treatment, Department of Physiology, College of Basic Medicine, Guizhou Medical University, Guiyang, Guizhou, China.
Guanyou HuangReproductive Medicine Center, the Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, China.
Jinnan LiReproductive Medicine Center, the Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, China.
Chao YangReproductive Medicine Center, the Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, China.
Aizhuan LongReproductive Medicine Center, the Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, China.
Jia TangReproductive Medicine Center, the Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, China.
Tengxiang ChenTransformation Engineering Research Center of Chronic Disease Diagnosis and Treatment, Department of Physiology, College of Basic Medicine, Guizhou Medical University, Guiyang, Guizhou, China.
Shuyun ZhaoReproductive Medicine Center, the Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, China.
Tuo ZhangTransformation Engineering Research Center of Chronic Disease Diagnosis and Treatment, Department of Physiology, College of Basic Medicine, Guizhou Medical University, Guiyang, Guizhou, China.ORCID https://orcid.org/0000-0003-3256-5930

Funding

Affiliated Hospital of Guizhou Medical University National Natural Science Foundation Cultivation Project gyfynsfc[2024]-13Guizhou Provincial Science and Technology Projects QKHJC[2024]Youth271Health Commission of Guizhou Province gzwkj2025-095Innovation and Entrepreneurship Training Program for College Students in Guizhou Province 2024106600509National Natural Science Foundation of China 82260291Pilot Program-China Reproductive Health Public Welfare Fund Project SZ202408
6 · The paper itself

Abstract

Poor ovarian response (POR) constitutes a notable clinical challenge within the domain of assisted reproductive technology, primarily attributable to the lack of reliable biomarkers for precise diagnosis and treatment. This study reveals significantly reduced levels of insulin-like growth factor 1 (IGF-1) in the serum, follicular fluid (FF), and granulosa cells (GCs) of patients with POR in comparison to those exhibiting a normal ovarian response (NOR). Notably, FF IGF-1 concentrations demonstrated significant positive correlations with crucial IVF outcomes, including the numbers of metaphase II (MII) oocytes, 2-pronuclear zygotes, and high-quality embryos. To establish causality, we employed complementary in vivo models: systemic insulin-like growth factor binding protein acid labile subunit (Igfals) knockout mice and granulosa cell specific IGF-1 receptor (Igf-1r) knockout mice. These models collectively demonstrated that disruption of the IGF-1 signaling axis impairs follicle-stimulating hormone (FSH) responsiveness and arrests follicular development at the secondary stage, thereby recapitulating the core POR phenotype. Building on these mechanistic insights, we developed novel clinical prediction tools based on FF IGF-1: a POR risk model [Area under the curve (AUC) = 0.914] and a pregnancy outcome nomogram (AUC = 0.893), both of which significantly outperform traditional ovarian reserve parameters (such as anti-Müllerian hormone and antral follicle count). Decision curve analysis (DCA) further validated a substantial clinical net benefit. This study aids clinicians in the early identification of patients with POR and provides a theoretical foundation for timely intervention and adjustment of treatment strategies.

Indexed as

BiomarkersInsulin-Like Growth Factor IOvulation InductionAdultAnimalsFemaleFollicular FluidGranulosa CellsHumansMiceMice, KnockoutBiomarkersInsulin-Like Growth Factor Iassisted reproductive technologygranulosa cellsIGF‐1poor ovarian responseprediction model

Identifiers

PMID41608982
PMCPMC13042885

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.